Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Aminosalicylates

8 evidence topics · 4 sources

Remission at Week 8 in two placebo-controlled induction trials of delayed-release mesalamine tablets
DoseStudy 1 (n=262) n/N (%)Study 2 (n=255) n/N (%)
Mesalamine 2.4 g/day“30/88 (34)”“34/84 (41)”
Mesalamine 4.8 g/day“26/89 (29)”“35/85 (41)”
Placebo“11/85 (13)”“19/86 (22)”